D-Lin-MC3-DMA
Based on 167 publication(s) in Google Scholar
D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.91%
- CAS No.: 1224606-06-7
- 화학식: C43H79NO2
- 분자량:642.09
-
보관:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Lipid Compound Library
HY-L043
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Liposome Library
HY-L214
-
Ionizable Lipid Compound Library
HY-L251
Publications Citing Use of MedChemExpress (MCE) D-Lin-MC3-DMA
More- Signal Transduct Target Ther. 2026 Mar 10;11(1):86. [Abstract]
- Science. 2026 Mar 5;391(6789):edau9394. [Abstract]
- Nat Biotechnol. 2025 Apr;43(4):539-544. [Abstract]
- Circulation. 2025 Dec 2;152(22):1586-1589. [Abstract]
- Nat Mater. 2024 Dec;23(12):1736-1747. [Abstract]
- Nat Nanotechnol. 2026 Mar 18. [Abstract]
- Nat Nanotechnol. 2026 Jan 14. [Abstract]
- Nat Nanotechnol. 2026 Jan 19. [Abstract]
- Nat Nanotechnol. 2023 Sep;18(9):1105-1114. [Abstract]
- Adv Mater. 2024 Jun 21:e2404784. [Abstract]
- Nat Biomed Eng. 2025 Jul 18. [Abstract]
- Nat Biomed Eng. 2024 Nov;8(11):1412-1424. [Abstract]
- Bioact Mater. 2024 May 14:38:486-498. [Abstract]
- Bioact Mater. 2024 May 23:39:273-286. [Abstract]
- Bioact Mater. 2023 Dec 22:34:125-137. [Abstract]
- Nat Chem. 2024 Oct;16(10):1687-1697. [Abstract]
- Adv Funct Mater. 2024 Oct 31.
- ACS Nano. 2026 Feb 3;20(4):3807-3820. [Abstract]
- ACS Nano. 2025 Dec 9;19(48):40798-40816. [Abstract]
- ACS Nano. 2025 Jan 14;19(1):1090-1102. [Abstract]
- ACS Nano. 2024 Sep 3;18(35):24204-24218. [Abstract]
- ACS Nano. 2023 Jul 25;17(14):13594-13610. [Abstract]
- ACS Nano. 2023 Jun 27;17(12):11454-11465. [Abstract]
- Nat Commun. 2025 Sep 25;16(1):8380. [Abstract]
- Nat Commun. 2025 May 29;16(1):4979. [Abstract]
- Nat Commun. 2023 May 11;14(1):2657. [Abstract]
- Nat Commun. 2024 Feb 26;15(1):1762. [Abstract]
- Nat Commun. 2024 Feb 29;15(1):1884. [Abstract]
- Nat Commun. 2023 Jan 17;14(1):75. [Abstract]
- Nat Commun. 2021 Dec 8;12(1):7101. [Abstract]
- Acta Pharm Sin B. 2024 Jul;14(7):3169-3183. [Abstract]
- Adv Sci (Weinh). 2026 Mar 24:e21507. [Abstract]
- Adv Sci (Weinh). 2025 Jun 20:e04195. [Abstract]
- Adv Sci (Weinh). 2024 Dec 31:e2404860. [Abstract]
- Nucleic Acids Res. 2026 Apr 13;54(7):gkag328. [Abstract]
- Biomaterials. 2026 Jul:330:124002. [Abstract]
- Biomaterials. 2026 Apr:327:123754. [Abstract]
- Sci Adv. 2021 Jan 13;7(3):eaba1028. [Abstract]
- Small. 2025 Jun 9:e2503749. [Abstract]
- Small. 2024 Jun 25:e2400643. [Abstract]
- J Biomed Sci. 2022 Dec 22;29(1):108. [Abstract]
- Mol Ther. 2026 Mar 3:S1525-0016(26)00178-4. [Abstract]
- J Control Release. 2026 May 23:396:115047. [Abstract]
- J Control Release. 2026 Mar 14:114825. [Abstract]
- J Control Release. 2026 Feb 8:392:114709. [Abstract]
- J Control Release. 2025 Dec 12:390:114539. [Abstract]
- J Control Release. 2025 Aug 7:386:114081. [Abstract]
- J Control Release. 2025 Sep 10:385:114027. [Abstract]
- J Control Release. 2025 Jun 18:113970. [Abstract]
- J Control Release. 2025 May 3:113811. [Abstract]
- J Control Release. 2025 May 20:113848. [Abstract]
- J Control Release. 2025 Apr 3:113687. [Abstract]
- J Control Release. 2025 Apr 18:113736. [Abstract]
- J Control Release. 2025 May 10:381:113571. [Abstract]
- J Control Release. 2024 Aug 2:373:738-748. [Abstract]
- J Control Release. 2024 May 29:371:179-192. [Abstract]
- Small Struct. 2026 Mar 6;7(3):e202500583.
- EBioMedicine. 2025 Mar:113:105599. [Abstract]
- Cell Rep Med. 2026 Mar 17;7(3):102667. [Abstract]
- J Immunother Cancer. 2024 Nov 9;12(11):e010249. [Abstract]
- Mater Today Bio. 2026 Jun 10:39:103340. [Abstract]
- J Colloid Interface Sci. 2024 Jun 23:674:139-144. [Abstract]
- Adv Healthc Mater. 2025 Aug 7:e00695. [Abstract]
- Angiogenesis. 2025 May 2;28(3):26. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307809121. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303567120. [Abstract]
- ACS Appl Mater Interfaces. 2024 May 16. [Abstract]
- Drug Deliv. 2023 Dec;30(1):2191891. [Abstract]
- Drug Deliv. 2022 Dec;29(1):2644-2657. [Abstract]
- Chem Sci. 2026 May 29. [Abstract]
- Anal Chem. 2022 Jun 28;94(25):9081-9090. [Abstract]
- NPJ Vaccines. 2026 Apr 15;11(1):116. [Abstract]
- Drug Deliv Transl Res. 2026 Jan 28. [Abstract]
- Drug Deliv Transl Res. 2024 Dec;14(12):3339-3353. [Abstract]
- Pharmaceutics. 2023 Mar 21;15(3):1009. [Abstract]
- Pharmaceutics. 2022 Oct 31;14(11):2357. [Abstract]
- Pharmaceutics. 2022 Oct 7;14(10):2129. [Abstract]
- Pharmaceutics. 2021 Nov 13;13(11):1924. [Abstract]
- Biomacromolecules. 2026 Feb 10. [Abstract]
- Int J Pharm. 2025 Nov 10:684:126186. [Abstract]
- Int J Pharm. 2024 Jul 25:124519. [Abstract]
- Int J Pharm. 2024 Jan 25:650:123688. [Abstract]
- Int J Pharm. 2023 Sep 25:644:123348. [Abstract]
- Int J Pharm. 2023 Apr 25:637:122896. [Abstract]
- Int J Pharm. 2021 Apr 15:599:120392. [Abstract]
- Int J Mol Sci. 2026 May 30;27(11):4968. [Abstract]
- J Drug Deliv Sci Technol. 2024 Sep.
- Eur J Pharm Sci. 2026 Jan 1:216:107383. [Abstract]
- Eur J Pharm Sci. 2025 Sep 1:212:107182. [Abstract]
- ACS Appl Bio Mater. 2024 Nov 18;7(11):7595-7607. [Abstract]
- ACS Appl Bio Mater. 2024 May 22. [Abstract]
- ACS Appl Bio Mater. 2024 Dec 16;7(12):7871-7882. [Abstract]
- Nucleic Acid Ther. 2023 Aug;33(4):248-264. [Abstract]
- Mol Ther Methods Clin Dev. 2023 May 11:29:450-459. [Abstract]
- Nanoscale Adv. 2022 Feb 4;4(9):2107-2123. [Abstract]
- Cell Rep Methods. 2024 Jan 22;4(1):100673. [Abstract]
- Mol Pharm. 2023 Aug 7;20(8):3876-3885. [Abstract]
- Mol Pharm. 2023 Aug 7;20(8):4285-4296. [Abstract]
- Mol Pharm. 2023 Jul 3;20(7):3356-3366. [Abstract]
- Eur J Pharm Biopharm. 2026 Jun 9:115146. [Abstract]
- ACS Omega. 2026 May 25;11(22):32321-32335. [Abstract]
- ACS Omega. 2025 Aug 1;10(31):34363-34371. [Abstract]
- Eur J Pharm Biopharm. 2024 Aug 20:114468. [Abstract]
- Eur J Pharm Biopharm. 2024 May:198:114242. [Abstract]
- Eur J Pharm Biopharm. 2024 Jan:194:95-109. [Abstract]
- J Chromatogr A. 2025 Apr 12:1746:465788. [Abstract]
- Sci Rep. 2026 May 21.
- Langmuir. 2026 Feb 3;42(4):3391-3399. [Abstract]
- J Biomed Mater Res A. 2022 May;110(5):1101-1108. [Abstract]
- Sci Rep. 2024 Jan 29;14(1):2403. [Abstract]
- Virol J. 2026 Apr 9;23(1):133. [Abstract]
- Anal Bioanal Chem. 2024 Oct;416(24):5281-5293. [Abstract]
- J Pharm Sci. 2023 May;112(5):1401-1410. [Abstract]
- J Microbiol Immunol Infect. 2023 Jun;56(3):516-525. [Abstract]
- Vaccine. 2025 May 14:57:127216. [Abstract]
- Vaccines. 2021 Sep 10;9(9):1007. [Abstract]
- Biosaf Health. 2026 May 12.
- Mol Immunol. 2026 Feb:190:101-109. [Abstract]
- Processes (Basel). 2025 Aug 5.
- J Phys Chem A. 2023 Oct 5;127(39):8220-8227. [Abstract]
- Biol Pharm Bull. 2025;48(11):1687-1693. [Abstract]
- Iran J Allergy Asthma Immunol. 2026 Jan 1;25(1):45-57. [Abstract]
- SSRN. 2026 Jun 18.
- bioRxiv. 2026 May 5.
- SSRN. 2026 May 26.
- Res Sq. 2026 May 14.
- bioRxiv. 2026 Apr 26:2026.04.25.720847. [Abstract]
- bioRxiv. 2026 Apr 27.
- bioRxiv. 2026 Apr 9.
- bioRxiv. 2026 Mar 26.
- bioRxiv. 2026 Mar 16.
- Preprints. 2026 Jan 1.
- bioRxiv. 2026 Jan 21.
- SSRN. 2025 Dec 1.
- bioRxiv. 2025 Dec 22:2025.12.18.694748. [Abstract]
- bioRxiv. 2025 Nov 4.
- SSRN. 2025 Oct 31.
- bioRxiv. 2025 Nov 11.
- bioRxiv. 2025 Sep 26.
- bioRxiv. 2025 Sep 29.
- Cell Investig. 2025 Aug 29.
- Patent. US20250248939A1.
- Patent. US20250243151A1.
- Patent. US20250235403A1.
- Patent. US20250205362A1.
- University of Toronto. 2025.
- Cell Investig. 2025 Sep.
- bioRxiv. 2025 Jun 25.
- bioRxiv. 2025 May 29:2025.05.26.656157. [Abstract]
- bioRxiv. 2025 March 10.
- bioRxiv. 2025 January 21.
- Patent. US20240309367A1.
- Ghent University. 2024.
- bioRxiv. 2024 July 31.
- bioRxiv. 2022 Dec 22:2022.12.22.521490. [Abstract]
- Brown University. 2024.
- bioRxiv. 2024 Apr 13.
- bioRxiv. 2024 Apr 12.
- University of Toronto. 2023 Nov.
- bioRxiv. 2023 Oct 4.
- bioRxiv. 2023 Oct 29:2023.10.21.563443. [Abstract]
- bioRxiv. 2023 Aug 14.
- OpenNano. 2023 May 8, 100161.
- Patent. US20230108926A1.
- Chemrxiv. Sep 29, 2022.
- Technische Universitat Dresden. 2022 Aug.
- bioRxiv. September 29, 2021.
Biological Activity
Preparation of MC3 Lipid Nanoparticles
Here we provide lipid molar ratios for LNPs in FDA-approved Patisiran (a siRNA targets the transthyretin (TTR) mRNA). The molar ratio of lipids in this formulation is D-Lin-MC3-DMA : DSPC : Cholesterol : PEG2000-C-DMG = 50 : 10 : 38.5 : 1.5[1], and RNA to lipid weight ratio is 0.05 (wt/wt).
A. Lipid Mixture Preparation
1. Dissolve lipids in ethanol and prepare 10 mg/m stock solutions. The lipid stock solutions can be stored at 20°C for later use.
Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.
Note 2: Cholesterol in solution should be kept warm (>37°C) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.
2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 548 μL of 10mg/mL D-Lin-MC3-DMA (HY-112251), 254 μL of 10mg/mL Cholesterol (HY-N0322), 134 μL of 10mg/mL DSPC (HY-W040193), and 64 μL of PEG2000-C-DMG (HY-145411) [2]. Mix the solutions thoroμghly to achieve a clear solution. This mixture contains 10 mg of total lipid.
Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.
B. siRNA Preparation
1. Prepare a 166.7 μg/mL siRNA solution with 100 mM pH 5 sodium acetate buffer.
Note 4: The lipid:siRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.
C. Mixing
There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.
It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.
1. Pipette Mixing Method:
1.1. Pipette 3 mL of the siRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20-30 seconds.
1.2. Incubate the resulting solution at room temperature for up to 15 minutes.
1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
2. Vortex Mixing Method:
1.1. Vortex 3 mL of siRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20-30 seconds.
1.2. Incubate the resulting solution at room temperature for up to 15 minutes.
1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
3. Microfluidic Mixing Method:
1.1 The 3 mL of siRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12 mL/min (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) in a microfluidic device.
Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.
1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
Reference
1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.
2. Curr Protoc. 2023;3(9):e898.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1224606-06-7
-
Appearance Liquid (Density: 0.886±0.06 g/cm3)
-
분자량 642.09
-
화학식 C43H79NO2
-
Color Colorless to light yellow
-
SMILES
O=C(OC(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (167)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma. [Abstract]2026 Mar 10;11(1):86. PMID: 41803088 -
Science
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction. [Abstract]2026 Mar 5;391(6789):edau9394. PMID: 41785353 -
Nat Biotechnol
2025 Apr;43(4):539-544. PMID: 39322763 -
Circulation
2025 Dec 2;152(22):1586-1589. PMID: 41325441 -
Nat Mater
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery. [Abstract]2024 Dec;23(12):1736-1747. PMID: 39223270 -
Nat Nanotechnol
2026 Mar 18. PMID: 41851499 -
Nat Nanotechnol
A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis. [Abstract]2026 Jan 14. PMID: 41535382 -
Nat Nanotechnol
Spatiotemporal targeting of messenger RNA lipid nanoparticles to the endometrium for the treatment of reproductive disorders. [Abstract]2026 Jan 19. PMID: 41555025 -
Nat Nanotechnol
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. [Abstract]2023 Sep;18(9):1105-1114. PMID: 37365276 -
Adv Mater
Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer-Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma. [Abstract]2024 Jun 21:e2404784. PMID: 38958110 -
Nat Biomed Eng
Mannich reaction-based combinatorial libraries identify antioxidant ionizable lipids for mRNA delivery with reduced immunogenicity. [Abstract]2025 Jul 18. PMID: 40681859 -
Nat Biomed Eng
Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. [Abstract]2024 Nov;8(11):1412-1424. PMID: 39578640 -
Bioact Mater
A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety. [Abstract]2024 May 14:38:486-498. PMID: 38779592 -
Bioact Mater
β-catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model. [Abstract]2024 May 23:39:273-286. PMID: 38832305 -
Bioact Mater
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach. [Abstract]2023 Dec 22:34:125-137. PMID: 38223537 -
Nat Chem
Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. [Abstract]2024 Oct;16(10):1687-1697. PMID: 38982196 -
-
ACS Nano
High-Throughput In Vivo Screening Identifies Structural Factors Driving mRNA Lipid Nanoparticle Delivery to the Brain. [Abstract]2026 Feb 3;20(4):3807-3820. PMID: 41555650 -
ACS Nano
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant. [Abstract]2025 Dec 9;19(48):40798-40816. PMID: 41289602 -
ACS Nano
Robust, Scalable Microfluidic Manufacturing of RNA-Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating. [Abstract]2025 Jan 14;19(1):1090-1102. PMID: 39700475 -
ACS Nano
Inhalable mRNA Nanoparticle with Enhanced Nebulization Stability and Pulmonary Microenvironment Infiltration. [Abstract]2024 Sep 3;18(35):24204-24218. PMID: 39174871 -
ACS Nano
2023 Jul 25;17(14):13594-13610. PMID: 37458484 -
ACS Nano
Correlating the Structure and Gene Silencing Activity of Oligonucleotide-Loaded Lipid Nanoparticles Using Small-Angle X-ray Scattering. [Abstract]2023 Jun 27;17(12):11454-11465. PMID: 37279108 -
Nat Commun
Buffer optimization of siRNA-lipid nanoparticles mitigates lipid oxidation and RNA-lipid adduct formation. [Abstract]2025 Sep 25;16(1):8380. PMID: 40998813 -
Nat Commun
2025 May 29;16(1):4979. PMID: 40442114 -
Nat Commun
Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. [Abstract]2023 May 11;14(1):2657. PMID: 37169757 -
Nat Commun
In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors. [Abstract]2024 Feb 26;15(1):1762. PMID: 38409275 -
Nat Commun
High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models. [Abstract]2024 Feb 29;15(1):1884. PMID: 38424061 -
Nat Commun
2023 Jan 17;14(1):75. PMID: 36650129 -
Nat Commun
Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. [Abstract]2021 Dec 8;12(1):7101. PMID: 34880218 -
Acta Pharm Sin B
M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy. [Abstract]2024 Jul;14(7):3169-3183. PMID: 39027257 -
Adv Sci (Weinh)
2026 Mar 24:e21507. PMID: 41875325 -
Adv Sci (Weinh)
Brachyury-Activated Fucoidan Hydrogel Microspheres Rejuvenate Degenerative Intervertebral Discs Microenvironment. [Abstract]2025 Jun 20:e04195. PMID: 40539715 -
Adv Sci (Weinh)
Loading of Extracellular Vesicles with Nucleic Acids via Hybridization with Non-Lamellar Liquid Crystalline Lipid Nanoparticles. [Abstract]2024 Dec 31:e2404860. PMID: 39741121 -
Nucleic Acids Res
Engineering polymeric RNA scaffolds as programmable combinatorial innate immune agonists. [Abstract]2026 Apr 13;54(7):gkag328. PMID: 41978258 -
Biomaterials
Transforming lipid nanoparticles into radio-activatable therapeutics through synergistic ferroptosis for enhanced cancer radiotherapy. [Abstract]2026 Jul:330:124002. PMID: 41570670 -
Biomaterials
Lipid nanoparticles that co-deliver poly(I:C) and short peptide antigens elicit anti-tumor responses with vaccination. [Abstract]2026 Apr:327:123754. PMID: 41075431 -
Sci Adv
2021 Jan 13;7(3):eaba1028. PMID: 33523869 -
Small
2025 Jun 9:e2503749. PMID: 40488967 -
Small
In Vivo Endothelial Cell Gene Silencing by siRNA-LNPs Tuned with Lipoamino Bundle Chemical and Ligand Targeting. [Abstract]2024 Jun 25:e2400643. PMID: 38923700 -
J Biomed Sci
Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants. [Abstract]2022 Dec 22;29(1):108. PMID: 36550570 -
Mol Ther
2026 Mar 3:S1525-0016(26)00178-4. PMID: 41782368 -
J Control Release
Antimicrobial peptide-derived lipid nanoparticles enable lung-targeted mRNA therapy for multidrug-resistant bacterial pneumonia. [Abstract]2026 May 23:396:115047. PMID: 42178062 -
J Control Release
Impact of ionizable lipid source on quality and stability of siRNA-loaded lipid nanoparticles. [Abstract]2026 Mar 14:114825. PMID: 41839265 -
J Control Release
Lipid nanoparticles containing zwitterionic lipids versatilely enhance the efficiency of mRNA delivery. [Abstract]2026 Feb 8:392:114709. PMID: 41666942 -
J Control Release
Understanding excipient interactions unlocks untapped potential of RNA-lipid nanoparticles in dry powder formulations for local pulmonary delivery. [Abstract]2025 Dec 12:390:114539. PMID: 41391722 -
J Control Release
Targeted lipolysis for obesity treatment: Cold atmospheric plasma-responsive nanoparticles amplify reactive oxygen species generation in adipocytes. [Abstract]2025 Aug 7:386:114081. PMID: 40754109 -
J Control Release
Efficacy versus immunogenicity of LNP-mediated delivery of mRNA and self-amplifying RNA upon intravitreal injection in the mouse eye. [Abstract]2025 Sep 10:385:114027. PMID: 40659060 -
J Control Release
Local delivery of IL-12 mRNA and indoximod prodrug potentiates antitumor immunity by increasing T cell effector function. [Abstract]2025 Jun 18:113970. PMID: 40541741 -
J Control Release
Delivery of Itgb1-siRNA by triptolide-modified and anti-Flt1 peptide-guided ionizable cationic LNPs for targeted therapy of corneal neovascularization. [Abstract]2025 May 3:113811. PMID: 40324532 -
J Control Release
Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: Refining paradigms. [Abstract]2025 May 20:113848. PMID: 40404049 -
J Control Release
Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery. [Abstract]2025 Apr 3:113687. PMID: 40187650 -
J Control Release
Lipid nanoparticles target neutrophils to reduce SARS-CoV-2-induced lung injury and inflammation. [Abstract]2025 Apr 18:113736. PMID: 40254136 -
J Control Release
Surfactant protein B-derived peptides as endosomal escape enhancers for pulmonary delivery of siRNA. [Abstract]2025 May 10:381:113571. PMID: 40010411 -
J Control Release
NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP. [Abstract]2024 Aug 2:373:738-748. PMID: 39053648 -
J Control Release
2024 May 29:371:179-192. PMID: 38795814 -
-
EBioMedicine
An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4+ T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis. [Abstract]2025 Mar:113:105599. PMID: 39955975 -
Cell Rep Med
Engineering lipid nanoparticle-stabilized emulsions for spatiotemporal mRNA delivery and enhanced T cell immunity. [Abstract]2026 Mar 17;7(3):102667. PMID: 41850240 -
J Immunother Cancer
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. [Abstract]2024 Nov 9;12(11):e010249. PMID: 39521615 -
Mater Today Bio
Identification of a cell subpopulation with different response to lipid nanoparticles and effect of protein corona on uptake and transfection. [Abstract]2026 Jun 10:39:103340. PMID: 42326074 -
J Colloid Interface Sci
2024 Jun 23:674:139-144. PMID: 38925059 -
Adv Healthc Mater
Pulmonary Delivery of siRNA Anti-TNFα-loaded Lipid Nanoparticles for Rapid Recovery in Murine Acute Lung Injury. [Abstract]2025 Aug 7:e00695. PMID: 40776451 -
Angiogenesis
2025 May 2;28(3):26. PMID: 40314870 -
Proc Natl Acad Sci U S A
Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies. [Abstract]2024 Mar 12;121(11):e2307809121. PMID: 38437543 -
Proc Natl Acad Sci U S A
2023 Aug 15;120(33):e2303567120. PMID: 37556502 -
ACS Appl Mater Interfaces
Electrophoretic Microfluidic Characterization of mRNA- and pDNA-Loaded Lipid Nanoparticles. [Abstract]2024 May 16. PMID: 38753459 -
Drug Deliv
Investigation of enhanced intracellular delivery of nanomaterials modified with novel cell-penetrating zwitterionic peptide-lipid derivatives. [Abstract]2023 Dec;30(1):2191891. PMID: 36964673 -
Drug Deliv
Single pot organic solvent-free thermocycling technology for siRNA-ionizable LNPs: a proof-of-concept approach for alternative to microfluidics. [Abstract]2022 Dec;29(1):2644-2657. PMID: 35949146 -
Chem Sci
Lipids and lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA delivery. [Abstract]2026 May 29. PMID: 42306548 -
Anal Chem
Spectroscopy-Based Local Modeling Method for High-Throughput Quantification of Nucleic Acid Loading in Lipid Nanoparticles. [Abstract]2022 Jun 28;94(25):9081-9090. PMID: 35700415 -
NPJ Vaccines
An mRNA vaccine confers enhanced protection against herpes simplex virus through an IFN-I-dependent pathway. [Abstract]2026 Apr 15;11(1):116. PMID: 41986380 -
Drug Deliv Transl Res
Overcoming size barriers in retinal gene therapy via lipid nanoparticle-mediated delivery of full-length eys DNA. [Abstract]2026 Jan 28. PMID: 41606207 -
Drug Deliv Transl Res
Realizing time-staggered expression of nucleic acid-encoded proteins by co-delivery of messenger RNA and plasmid DNA on a single nanocarrier. [Abstract]2024 Dec;14(12):3339-3353. PMID: 39009932 -
Pharmaceutics
DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice. [Abstract]2023 Mar 21;15(3):1009. PMID: 36986871 -
Pharmaceutics
Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability. [Abstract]2022 Oct 31;14(11):2357. PMID: 36365175 -
Pharmaceutics
2022 Oct 7;14(10):2129. PMID: 36297564 -
Pharmaceutics
Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems. [Abstract]2021 Nov 13;13(11):1924. PMID: 34834339 -
Biomacromolecules
Selective mRNA Delivery to Activated Macrophages via Hyaluronic Acid-Functionalized Lipid Nanoparticles with Optimized PEGylation. [Abstract]2026 Feb 10. PMID: 41666458 -
Int J Pharm
Deciphering the role of polyethylene glycol-lipid anchors in siRNA-LNP efficacy for P2y2 inhibition in bone marrow-derived macrophages. [Abstract]2025 Nov 10:684:126186. PMID: 40967321 -
Int J Pharm
DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cells. [Abstract]2024 Jul 25:124519. PMID: 39067551 -
Int J Pharm
Effect of Lipid Composition on RNA-Lipid Nanoparticle Properties and Their Sensitivity to Thin-Film Freezing and Drying. [Abstract]2024 Jan 25:650:123688. PMID: 38070660 -
Int J Pharm
Repositioning the over-the-counter antihistamine ebastine as an intracellular siRNA delivery enhancer. [Abstract]2023 Sep 25:644:123348. PMID: 37633539 -
Int J Pharm
Influence of lipid composition of messenger RNA-loaded lipid nanoparticles on the protein expression via intratracheal administration in mice. [Abstract]2023 Apr 25:637:122896. PMID: 36972778 -
Int J Pharm
Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles. [Abstract]2021 Apr 15:599:120392. PMID: 33639228 -
Int J Mol Sci
Poly(I:C) Lipoamino Bundle LNPs Induce Tumor Cytotoxicity and Immune Activation with Enhanced Efficacy by Survivin Silencing. [Abstract]2026 May 30;27(11):4968. PMID: 42278494 -
-
Eur J Pharm Sci
Impact of formulation and process parameters on the stability and bioactivity of RNA-loaded lipid nanoparticles during nebulization. [Abstract]2026 Jan 1:216:107383. PMID: 41265762 -
Eur J Pharm Sci
The impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance for pulmonary delivery. [Abstract]2025 Sep 1:212:107182. PMID: 40571267 -
ACS Appl Bio Mater
Diblock Copolymer Targeted Lipid Nanoparticles: Next-Generation Nucleic Acid Delivery System Produced by Confined Impinging Jet Mixers. [Abstract]2024 Nov 18;7(11):7595-7607. PMID: 39480746 -
ACS Appl Bio Mater
Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles. [Abstract]2024 May 22. PMID: 38775109 -
ACS Appl Bio Mater
Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. [Abstract]2024 Dec 16;7(12):7871-7882. PMID: 38558434 -
Nucleic Acid Ther
Mammalian Target of Rapamycin Inhibition Enhances Delivery and Activity of Antisense Oligonucleotides in Uveal Melanoma Cells. [Abstract]2023 Aug;33(4):248-264. PMID: 37389884 -
Mol Ther Methods Clin Dev
Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution. [Abstract]2023 May 11:29:450-459. PMID: 37251983 -
Nanoscale Adv
Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. [Abstract]2022 Feb 4;4(9):2107-2123. PMID: 36133441 -
Cell Rep Methods
A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity. [Abstract]2024 Jan 22;4(1):100673. PMID: 38171361 -
Mol Pharm
Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection. [Abstract]2023 Aug 7;20(8):3876-3885. PMID: 37491979 -
Mol Pharm
Process Robustness in Lipid Nanoparticle Production: A Comparison of Microfluidic and Turbulent Jet Mixing. [Abstract]2023 Aug 7;20(8):4285-4296. PMID: 37462906 -
Mol Pharm
Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine. [Abstract]2023 Jul 3;20(7):3356-3366. PMID: 36952227 -
Eur J Pharm Biopharm
Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood. [Abstract]2026 Jun 9:115146. PMID: 42264006 -
ACS Omega
Delivery of Monomethyl Auristatin E Using Ionizable Lipid Nanoparticles for B‑Cell Acute Lymphoblastic Leukemia Treatment. [Abstract]2026 May 25;11(22):32321-32335. PMID: 42294239 -
ACS Omega
Enhanced Accumulation of Heteroduplex Oligonucleotides in Dystrophin-Deficient Skeletal Muscles by Single Oligonucleotide-Loaded Unit Polyion Complexes. [Abstract]2025 Aug 1;10(31):34363-34371. PMID: 40821543 -
Eur J Pharm Biopharm
Synthesis of a novel adapter lipid using Fc-region mediated antibody modification for post-insert preparation of transferrin receptor targeted messenger RNA-loaded lipid nanoparticles. [Abstract]2024 Aug 20:114468. PMID: 39173936 -
Eur J Pharm Biopharm
Tailoring lipid nanoparticles for T-cell targeting in allergic Asthma: Insights into efficacy and specificity. [Abstract]2024 May:198:114242. PMID: 38442794 -
Eur J Pharm Biopharm
Lipoamino bundle LNPs for efficient mRNA transfection of dendritic cells and macrophages show high spleen selectivity. [Abstract]2024 Jan:194:95-109. PMID: 38065313 -
J Chromatogr A
A platform method for simultaneous quantification of lipid and nucleic acid components in lipid nanoparticles. [Abstract]2025 Apr 12:1746:465788. PMID: 39987694 -
-
Langmuir
Monodisperse mRNA-Loaded Lipid Nanoparticles Enabled by Optimizing an Ionizable Cationic Lipid. [Abstract]2026 Feb 3;42(4):3391-3399. PMID: 41534094 -
J Biomed Mater Res A
2022 May;110(5):1101-1108. PMID: 35076171 -
Sci Rep
A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. [Abstract]2024 Jan 29;14(1):2403. PMID: 38287070 -
Virol J
An LNP antiviral siRNA drug cocktail delivered intranasally is effective against a range of respiratory viruses. [Abstract]2026 Apr 9;23(1):133. PMID: 41957800 -
Anal Bioanal Chem
Development of an advanced separation and characterization platform for mRNA and lipid nanoparticles using multi-detector asymmetrical flow field-flow fractionation. [Abstract]2024 Oct;416(24):5281-5293. PMID: 39102094 -
J Pharm Sci
Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice. [Abstract]2023 May;112(5):1401-1410. PMID: 36596392 -
J Microbiol Immunol Infect
Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. [Abstract]2023 Jun;56(3):516-525. PMID: 36934064 -
Vaccine
Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue. [Abstract]2025 May 14:57:127216. PMID: 40373693 -
Vaccines
Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque. [Abstract]2021 Sep 10;9(9):1007. PMID: 34579244 -
-
Mol Immunol
2026 Feb:190:101-109. PMID: 41564652 -
-
J Phys Chem A
2023 Oct 5;127(39):8220-8227. PMID: 37733882 -
Biol Pharm Bull
Treatment of Experimental Autoimmune Encephalomyelitis with Lipid Nanoparticles Loaded with siRNA Targeting Neogenin. [Abstract]2025;48(11):1687-1693. PMID: 41183892 -
Iran J Allergy Asthma Immunol
In vitro Safety and Immunotoxicity Assessment of a Novel mRNA-LNP Vaccine against Cytomegalovirus: Insights into Safety and Immunomodulatory Profiles. [Abstract]2026 Jan 1;25(1):45-57. PMID: 41674172 -
-
-
-
-
bioRxiv
Intranasal CRISPR-lipid nanoparticles targeting MAPK9 reduce neuroinflammation after traumatic brain injury. [Abstract]2026 Apr 26:2026.04.25.720847. PMID: 42079190 -
-
-
-
-
-
-
-
bioRxiv
Telomerase mRNA-Lipid nanoparticles attenuate neuroinflammation after traumatic brain injury in mice. [Abstract]2025 Dec 22:2025.12.18.694748. PMID: 41509282 -
-
-
-
-
-
-
-
-
-
-
-
-
-
bioRxiv
Automated and parallelized microfluidic generation of large and precisely-defined lipid nanoparticle libraries. [Abstract]2025 May 29:2025.05.26.656157. PMID: 40501993 -
-
-
-
-
-
bioRxiv
2022 Dec 22:2022.12.22.521490. PMID: 36597546 -
-
-
-
-
-
bioRxiv
2023 Oct 29:2023.10.21.563443. PMID: 37904991 -
-
-
-
-
-
용액&용해도
DMSO : 200 mg/mL (311.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 125 mg/mL (194.68 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (7.79 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (7.79 mM); Clear solution; Need ultrasonic and warming and heat to 80°C
This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387. [Content Brief]
[2]. Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022;19(7):2175-2182. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.5574 mL | 7.7871 mL | 15.5741 mL | 38.9354 mL |
| 5 mM | 0.3115 mL | 1.5574 mL | 3.1148 mL | 7.7871 mL | |
| 10 mM | 0.1557 mL | 0.7787 mL | 1.5574 mL | 3.8935 mL | |
| 15 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL | 2.5957 mL | |
| 20 mM | 0.0779 mL | 0.3894 mL | 0.7787 mL | 1.9468 mL | |
| 25 mM | 0.0623 mL | 0.3115 mL | 0.6230 mL | 1.5574 mL | |
| 30 mM | 0.0519 mL | 0.2596 mL | 0.5191 mL | 1.2978 mL | |
| 40 mM | 0.0389 mL | 0.1947 mL | 0.3894 mL | 0.9734 mL | |
| 50 mM | 0.0311 mL | 0.1557 mL | 0.3115 mL | 0.7787 mL | |
| 60 mM | 0.0260 mL | 0.1298 mL | 0.2596 mL | 0.6489 mL | |
| 80 mM | 0.0195 mL | 0.0973 mL | 0.1947 mL | 0.4867 mL | |
| 100 mM | 0.0156 mL | 0.0779 mL | 0.1557 mL | 0.3894 mL |
D-Lin-MC3-DMA Related Classifications
HY-112251 Related Classifications
Powered by Bioz